Overview


According to FutureWise analysis the market for antidiabetics in 2023 is US$ 97.96 billion, and is expected to reach US$ 207.25 billion by 2031 at a CAGR of 9.80%.

Antidiabetic drugs are medicines designed to stabilize and control blood glucose levels among individuals with diabetes. Antidiabetic drugs are typically used to control diabetes. Diabetes is caused by the body’s incapacity to generate or respond to the pancreatic hormone insulin. One of the crucial physiological actions of insulin is to control blood glucose levels. Glucose is an essential nutrient for cellular metabolism, and cells must accept neither too little nor too much. The deficiency in the pancreatic secretion of insulin, or scarcity of tissue sensitivity to the hormone, potentially leads to diabetes, the primary component of which is boosted blood glucose levels (hyperglycemia). Patients are generally classified into two types: type I diabetes, characterized by a lack of production of insulin, and type II diabetes, characterized by resistance of tissue to the insulin produced by the pancreas.

Type II diabetes may often be treated with oral hypoglycemic or antihyperglycemic drugs instead of insulin. The sulfonylureas, for example, promote the insulin-secreting beta cells of the pancreas to boost insulin production. This effect seems to diminish with long-term use, but plasma glucose levels remain lower. The most severe side effect of these drugs, which occurs only infrequently, is profound hypoglycemia; in severe circumstances, this can lead to a coma. Repaglinide and nateglinide, belonging to the class of compounds known as meglitinides, are other orally active compounds that promote insulin release from the pancreas. These compounds work by closing potassium channels on the surface of beta cells, leading to an influx of calcium ions within the cells and subsequently causing the outflow of insulin from cellular storage vesicles.

FutureWise Market Research has published a report that provides an insightful analysis antidiabetics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antidiabetics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • AstraZeneca
  • Bayer Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb.
  • Eli Lilly.
  • Halozyme Therapeutics
  • Johnson and Johnson
  • MerckCo. Inc.
  • Novartis AG
  • Novo Nordisk
  • Oramed Pharmaceuticals Inc.
  • Pfizer
  • Sanofi
  • Takeda Pharmaceutical

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antidiabetics Market:

  • In May 2022, the FDA approved a new drug for individuals with Type 2 diabetes. The drug Tirzepatide is a once-a-week injection that helps individuals manage their blood glucose levels and reduce food intake.
  • In March 2022, Oramed reported that ORMD-0801, a novel molecule, was tested in two pivotal Phase 3 trials and may one-day serve as the first and most practical oral insulin capsule for administering insulin therapy. This medication is anticipated to revolutionize oral anti-diabetes and insulin markets. An oral GLP-1 (glucagon-like peptide-1) analog capsule (ORMD-0901) is also being developed by Oramed.

The increasing prevalence of diabetes, produced by sedentary lifestyles, poor dietary habits, and an aging demographic, is anticipated to be a significant driver in the antidiabetics market. The modern way of living, indicated by reduced physical exercise and an increased consumption of processed foods, has contributed to a rise in diabetes cases. Also, as populations age, the incidence of diabetes innately rises, creating a sustained need for antidiabetic drugs. This demographic change, mixed with lifestyle preferences, stressed a constant demand for effective pharmaceutical treatments to manage and treat diabetes. Moreover, the launches of innovative antidiabetic products are significantly bolstering the growth of the antidiabetics market during the forecast period. Recent advances in pharmaceutical R&D have potentially led to the launch of novel and more efficacious antidiabetic drugs. These products often offer enhanced effectiveness, tolerability, and improved patient convenience, compelling increased adoption rates. For instance, in May 2021, F.Hoffmann-La Roche Ltd. launched an antidiabetic pump known as mySugar Pump Control under the mySugar app. mySugar Pump Control allows patients to control indulin pumps through smartphones to import and view the data status. Also, the introduction of combination therapies and targeted therapies in drug development has extended the treatment options open, further driving the antidiabetics market. However, the high cost of certain antidiabetic drugs may restrain the market expansion. While these novel drugs usually offer several benefits, their high expense may pose a significant financial barrier for patients, especially those without sufficient insurance coverage and residing in areas with limited access to medical resources. Therefore hindering the target market over the projection period.
 

By Product

  • Insulin-based Antidiabetics
    • Rapid-Acting Analog
    • Long-Acting Analog
    • Premixed Insulin
    • Short-Acting Analog
    • Intermediate-Acting Insulin
  • Antidiabetics Drug Class
    • Alpha-Glucosidases Inhibitors
    • Biguanides
    • Sulphonylureas
    • GLP-1 (Glucagon-like peptide) Agonists
    • DPP-IV (Dipeptidyl Peptidase) Inhibitors
    • Meglitinides
    • SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors
    • Thiazolidinedione

By Patient Population

  • Pediatrics
  • Adults
  • Geriatrics

By Route of Administration

  • Insulin Syringes/ Insulin Pens
  • Insulin Pumps
  • Intravenous Infusion
  • Oral
  • Other Routes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to factors such as increasing diabetic cases, a growing geriatric population, increasing investment in drug development, an increasing number of drug approvals by the FDA, product launches, and increasing investment in research and development are expected to drive the growth of the antidiabetics market over the forecast period in the region. For instance, in May 2022, the FDA approved Eli Lilly's diabetes drug, Mounjaro, a first-of-its-kind treatment that can help control patients' blood sugar. In addition, sophisticated healthcare infrastructure, technological advancements, and reimbursement frameworks are further propelling the target market in the area.

 

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antidiabetics Market By Product, By Patient Population, By Route of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antidiabetics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antidiabetics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antidiabetics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antidiabetics Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Insulin-based Antidiabetics
         1.1. Rapid-Acting Analog
         1.2. Long-Acting Analog
         1.3. Premixed Insulin
         1.4. Short-Acting Analog
         1.5. Intermediate-Acting Insulin
        2. Antidiabetics Drug Class
         2.1. Alpha-Glucosidases Inhibitors
         2.2. Biguanides
         2.3. Sulphonylureas
         2.4. GLP-1 (Glucagon-like peptide) Agonists
         2.5. DPP-IV (Dipeptidyl Peptidase) Inhibitors
         2.6. Meglitinides
         2.7. SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors
         2.8. Thiazolidinedione

  • 8.   Antidiabetics Market, By Patient Population Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pediatrics
        2. Adults
        3. Geriatrics

  • 9.   Antidiabetics Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Insulin Syringes/ Insulin Pens
        2. Insulin Pumps
        3. Intravenous Infusion
        4. Oral
        5. Other Routes

  • 10.   North America Antidiabetics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antidiabetics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antidiabetics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antidiabetics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bayer Corporation
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Boehringer Ingelheim
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bristol-Myers Squibb.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Eli Lilly.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Halozyme Therapeutics
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Johnson & Johnson
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MerckCo. Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Novo Nordisk
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Oramed Pharmaceuticals Inc.
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Pfizer
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Sanofi
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Takeda Pharmaceutical
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Diabetics Assays Market

Read More
Partner

Our Clients